InVivoMAb anti-mouse CTLA-4 (CD152, Clone: 9D9) | Bio X Cell
Anti-mouse PD-1 (CD279) Antibody | Recombinant RMP1-14 | InvivoGen
Frontiers | Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
Frontiers | PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Anti-PD-1 Blocking Antibody Inhibits Murine Melanoma Growth in... | Download Scientific Diagram
Role of PD-1 during effector CD8 T cell differentiation | PNAS
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker - Wang - 2020 - Cancer Medicine - Wiley Online Library
Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody - RSC Advances (RSC Publishing)
A. C57BL/6 mice were intraperitoneally treated with an anti-PD-1... | Download Scientific Diagram
Anti-mouse PD-1 (CD279) Antibody | Recombinant RMP1-14 | InvivoGen
Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy | Science Advances
PD-1 Specific 'Blocking' Antibodies That Deplete PD-1+ T Cells Present An Inconvenient Variable In Pre-clinical Immunotherapy Experiments | bioRxiv
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer | Journal for ImmunoTherapy of Cancer
PD-L1 Neutralizing Antibody
The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy - ScienceDirect
PD-1 Specific 'Blocking' Antibodies That Deplete PD-1+ T Cells Present An Inconvenient Variable In Pre-clinical Immunotherapy Experiments | bioRxiv
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer: Molecular Therapy
Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy | PLOS ONE
CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy | Acta Pharmacologica Sinica
Release the B7.1! Anti-PD-L1 breaks PD-L1's grip
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | NEJM
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD- L1 Axis - ScienceDirect
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy | Journal of the American Chemical Society
Anti-PD-1 Blocking Antibody Inhibits Human Melanoma Xenograft Growth in... | Download Scientific Diagram
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance | Nature Immunology
